Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Accumulated Expenses data on file, last reported at $5.6 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.6 million, down 12.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (down 12.8% YoY), and the FY2025 annual result was $7.6 million, up 2.39% from the prior year.
• Accumulated Expenses declined to $5.6 million in Q1 2026 per ARTV's latest filing, from $7.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $7.6 million in Q4 2025 and troughed at $3.6 million in Q2 2025.
• A 4-year average of $5.7 million and a median of $5.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses soared 82.65% in 2024, then slumped 41.26% in 2025.
• A 4-year view of Accumulated Expenses shows it stood at $4.0 million in 2023, then soared by 82.65% to $7.4 million in 2024, then rose by 2.39% to $7.6 million in 2025, then fell by 26.56% to $5.6 million in 2026.
• Business Quant data shows ARTV's Accumulated Expenses at $5.6 million in Q1 2026, $7.6 million in Q4 2025, and $5.6 million in Q3 2025.